2-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosis
Standard therapy of high risk patients with Langerhans cell histiocytosis (LCH) is associated with essential risk of therapy failure. In the present study results of 2-clorodeoxyadenosine usage as alternative therapy in this group of patients are analyzed. In this study 31 patients with multisystem...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/725 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241185264074752 |
|---|---|
| author | G. G. Solopova D. D. Baidildina L. I. Zharikova I. I. Kalinina U. N. Petrova Ye. V. Suntsova O. V. Goronkova L. A. Hachatryan V. V. Sinitsina G. A. Novichkova A. A. Maschan M. A. Maschan |
| author_facet | G. G. Solopova D. D. Baidildina L. I. Zharikova I. I. Kalinina U. N. Petrova Ye. V. Suntsova O. V. Goronkova L. A. Hachatryan V. V. Sinitsina G. A. Novichkova A. A. Maschan M. A. Maschan |
| author_sort | G. G. Solopova |
| collection | DOAJ |
| description | Standard therapy of high risk patients with Langerhans cell histiocytosis (LCH) is associated with essential risk of therapy failure. In the present study results of 2-clorodeoxyadenosine usage as alternative therapy in this group of patients are analyzed. In this study 31 patients with multisystem form LCH with involving of organs at risk were included. Nineteen patients have received Prednisone and Vinblastine as front line therapy (standard group). Nine patients have received therapy with 2-CdA and cytosine-arabinoside (group 2-CdA). The patients in standard group statistically significant more often (55.5 % vs. 0 %, р = 0.0095) required second line therapy. Permanent disease conse-quences was more often developed in standard group (63.6 % vs. 0 %, р = 0.0147). The overall survival was 65.7 ± 12,8 % among standard group patients and 88.8% ±10% in 2-CdA group; p = 0.27. The event-free survival was in standard group 33.9 ± 12 %, in 2-CdA group – 88.8 ± 10 %, p = 0.0207. Severe hematological toxicity was observed at 2-CdA therapy. 2-CdA therapy is highly effective in treatment of high risk patients with LCH. The drug should be used only in a specialized hospital. |
| format | Article |
| id | doaj-art-aff35ebb6ec14d3cbe54f0f6a680cf5f |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-aff35ebb6ec14d3cbe54f0f6a680cf5f2025-08-20T04:00:14ZrusABV-pressОнкогематология1818-83462413-40232022-11-01038156032-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosisG. G. Solopova0D. D. Baidildina1L. I. Zharikova2I. I. Kalinina3U. N. Petrova4Ye. V. Suntsova5O. V. Goronkova6L. A. Hachatryan7V. V. Sinitsina8G. A. Novichkova9A. A. Maschan10M. A. Maschan11Federal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Children Clinical HospitalFederal Research Center of Pediatric Hematology, Oncology and ImmunologyRussian Children Clinical HospitalRussian Children Clinical HospitalМинздравсоцразвития РоссииFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyStandard therapy of high risk patients with Langerhans cell histiocytosis (LCH) is associated with essential risk of therapy failure. In the present study results of 2-clorodeoxyadenosine usage as alternative therapy in this group of patients are analyzed. In this study 31 patients with multisystem form LCH with involving of organs at risk were included. Nineteen patients have received Prednisone and Vinblastine as front line therapy (standard group). Nine patients have received therapy with 2-CdA and cytosine-arabinoside (group 2-CdA). The patients in standard group statistically significant more often (55.5 % vs. 0 %, р = 0.0095) required second line therapy. Permanent disease conse-quences was more often developed in standard group (63.6 % vs. 0 %, р = 0.0147). The overall survival was 65.7 ± 12,8 % among standard group patients and 88.8% ±10% in 2-CdA group; p = 0.27. The event-free survival was in standard group 33.9 ± 12 %, in 2-CdA group – 88.8 ± 10 %, p = 0.0207. Severe hematological toxicity was observed at 2-CdA therapy. 2-CdA therapy is highly effective in treatment of high risk patients with LCH. The drug should be used only in a specialized hospital.https://oncohematology.abvpress.ru/ongm/article/view/725langerhans cell histiocytosis2-clorodeoxyzdenosinecytosine-arabinosidepolychemotherapy |
| spellingShingle | G. G. Solopova D. D. Baidildina L. I. Zharikova I. I. Kalinina U. N. Petrova Ye. V. Suntsova O. V. Goronkova L. A. Hachatryan V. V. Sinitsina G. A. Novichkova A. A. Maschan M. A. Maschan 2-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosis Онкогематология langerhans cell histiocytosis 2-clorodeoxyzdenosine cytosine-arabinoside polychemotherapy |
| title | 2-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosis |
| title_full | 2-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosis |
| title_fullStr | 2-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosis |
| title_full_unstemmed | 2-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosis |
| title_short | 2-Clorodeoxyadenosine in therapy of children with Langerhans cell histiocytosis |
| title_sort | 2 clorodeoxyadenosine in therapy of children with langerhans cell histiocytosis |
| topic | langerhans cell histiocytosis 2-clorodeoxyzdenosine cytosine-arabinoside polychemotherapy |
| url | https://oncohematology.abvpress.ru/ongm/article/view/725 |
| work_keys_str_mv | AT ggsolopova 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT ddbaidildina 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT lizharikova 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT iikalinina 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT unpetrova 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT yevsuntsova 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT ovgoronkova 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT lahachatryan 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT vvsinitsina 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT ganovichkova 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT aamaschan 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis AT mamaschan 2clorodeoxyadenosineintherapyofchildrenwithlangerhanscellhistiocytosis |